Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 88.5%

Neg 88.5% Neu 0% Pos 0%

Evercore ISI Group analyst Cory Kasimov downgrades Upstream Bio (NASDAQ:UPB) from Outperform to In-Line and lowers the price target from $40 to $15.